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Abstract. Aurora A kinase is overexpressed in many cancers but the status of this protein in the breast cancer often varies.
We investigate the expression and localization of Aurora A protein in relation with tumor emergence and progression in breast
cancer. Aurora A kinase status was evaluated in 107 patients using immunohistochemistry. The experimental ﬁndings showed
that high expression of the Aurora A protein was correlated with elevated nuclear grade, low expression of progesterone receptor
and positive nodal status. The experimental results showed also that the localization of this kinase shifts from cytoplasm in non
malignant adjacent tissue to both cytoplasmic and nuclear compartments in tumoral tissue, suggesting an oncogenic role of the
nuclear accumulation. We have, furthermore, detected the overexpression of this protein in non malignant adjacent tissue. The
expression of the Aurora A kinase in non malignant tissue may represent an earlier diagnosis tool for breast cancer.
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1. Introduction
The Aurora A protein is a Serine/Threonine kinase,
with 403 amino acids and 46 kilodaltons (Kda) as
molecular weight [1]. This kinase plays a crucial role
during mitosis [2,3]. It acts as a key regulator of mul-
tiple mitotic events: centrosome maturation and sepa-
ration [4], regulation of spindle assembly [5,6], equal
segregation of chromosomes and cytokinesis [7]. Au-
rora A is a cell-cycle regulated protein [8], and this
centrosome-associated kinase is active and expressed
at a high level during G2-M phases [9–11]. This pro-
tein is degraded at the end of mitosis [12–15]. In nor-
mal tissue Aurora A is restrained to the centrosomes
while in late phases of mitosis it is located at the spin-
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dle poles. Overexpression of this kinase alters centro-
some number and function leading to aberrant mitotic
spindle, missegregation of chromosomes and cellular
transformation [16]. Errors in the mitotic process are
considered to be one of the major causes of genetic
instability that hallmarks cancer [17].
Hence Aurora A is an oncogenic protein encoded by
the oncogeneSTK 15 located on chromosome20q13.2,
which is a highly ampliﬁed region in various human
tumors such as the esophageal squamous cell carcino-
ma [18], the colorectal carcinomas [19], the ovarian
and gastric cancers [21], humangliomas [22] and breast
cancer [23,24]. Moreover, mRNA of STK15 is report-
ed to be enhanced in various cancers [23–26]. Poly-
morphisms in this gene are associated with increased
risk of several cancers [27–31] particularly in breast
cancer [32].
Aurora A protein is frequently overexpressed in sev-
eral human cancers: lung [33], head and neck [34],
ovarian [35,36], colon [37], prostate [38], pancr-
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eas [39], esophagus [40] and breast one [41], as shown
by immunohistochemistry (IHC).
In breast cancer, aneuploidy (abnormal number of
chromosomes) is highly prevalent, probably associated
with Aurora A; which has been initially identiﬁed as
BTAK: Breast Tumor Ampliﬁed Kinase [1,42]. Breast
cancer is the most common type of cancer for women,
it’s a hormone related tumor with various grade and
stage presentations. Some studies were conducted to
assess rate expression of AuroraA protein and to reveal
its role in breast cancer [41,43–45]. The aim of this
study is to investigate the expression level and subcel-
lular localization of AuroraA and to establish if there is
any relationship with clinical variables in breast cancer.
2. Materials and methods
2.1. Clinical tissue sample
107 archival parafﬁn-embedded tumor sections were
collected at the Oncology Institute of Saleh Azaı¨ez
(ISA). They have been obtained from patients who un-
derwent surgery with pathologically conﬁrmed breast
cancer, and admitted to the institute between 1999 and
2010. The following clinical data were collected: age,
histological subtype, tumor grade (SBR: Scarff Bloom
and Richardson) tumor size, progesterone and estro-
gen receptors expression (RP, RE), nodal status, nu-
clear grade and ﬁnally, mitotic index. The patients’
characteristics are shown in Table 1. The study pro-
tocol was approved by the head of the department of
histopathology at the ISA institute.
2.2. Antibodies
For this study we used the 6F11 monoclonal anti-
body for Estrogen Receptor (Novocastra Laboratories,
UK) and the PgR636 monoclonal antibody for Proges-
terone Receptor (Novocastra Laboratories, UK). For
AuroraA protein detectionwe used amousemonoclon-
al antibody (clone 35c1), which was developed against
the non catalytic N-terminal domain of the kinase; this
clone was tested on several breast cancer cell lines:
MCF-7, S68, T47D, MDA-MB-468 and SK-Br-3, at
the UMR6061 in the Institute of Genetics and Devel-
opment of Rennes, France [46].
2.3. Western blot
The speciﬁcity of the Aurora A antibody has been
tested on different human cell lines lysates: Hek 293,
Table 1
Patient characteristics (n = 107)
Characteristic Number of
patients [%]
Age [years]
Median 45
Range 24–85
Histological subtype
Invasive ductal carcinoma 95 [88.8]
Lobular carcinoma 8 [7.5]
Other histology 4 [3.7]
SBR
I 15 [14]
II 50 [46.7]
III 42 [39.3]
Tumor Size
T1 [< 20 MM] 14 [14.2]
T2 [ 20MM and  50MM] 72 [72.7]
T3 [> 50MM] 13 [13.1]
Unknown 8
Receptor status
RE+ RP+ 38 [56.7]
RE- RP- 17 [25.4]
RE+ RP- 7 [10.4]
RE- RP+ 5 [7.5]
Unknown 40
Nodal status
N+ 56 [70.9]
N- 23 [29.1]
Unknown 28
Nuclear grade
I 16 [15.7]
II 55 [53.9]
III 31 [30.4]
Unknown 5
Mitotic index [nb of mitotic cell/ 10 HPFs+]
1 [0 – 5] 40[41.0]
2 [6 – 10] 24[35.0]
3 [> 11] 33[34.0]
Unknown 10
+HPFs: high-power ﬁelds.
Hela, RCC4+ and RCC4− (ATCC, USA), and also on
the recombinant human His-Aurora A protein experi-
enced with an increasing concentration. Lysate from
each cell line was separated by 12% SDSPAGE, and
the migration was made, in parallel, with the molecu-
lar weight standards (low range, Bio-Rad Laboratories,
CA); then we transferred separated proteins to nitrocel-
lulose membrane (HybondAmersham, GE Healthcare,
UK). The membranes were blocked in 5% skim milk
in a TBS-T. We probed with the Aurora A antibody
in 2.5% skim milk in a TBS-T. Finally, we incubat-
ed with a secondary antibody: peroxidase-conjugated
secondary mouse antibody (Jackson ImmunoResearch
Laboratories,UK). The protein band was visualized by
enhanced chemiluminescence (ECL) (AmershamPhar-
macia Biotech, FR) West Pico or Dura (Pierce, Rock-
ford, IL).
I. Ferchichi et al. / Assessment of Aurora A kinase expression in breast cancer: A tool for early diagnosis? 65
Fig. 1. A and B: Immunostaining of colorectal carcinoma (x400): (A): with anti-Aurora-A antibody: positive control, (B): without anti-Aurora-A
antibody: ne´gative control. C, D, E and F: Aurora-A immunostaining in human mammary malignant tissue (x400), brown color indicates
antibody binding and intensity of staining is: (C): 0 negative staining, (D): +1 weakly positive staining, (E): +2 moderately positive staining, (F):
+3 strongly positive staining. G: Aurora-A immunostaining in lobular mammary non malignant tissue (x400). By using the autologous antibody
of Aurora-A protein on a histological section of non malignant lobular mammary, adjacent to the tumor tissue, we observe a staining of this
protein in the cytoplasm. (Colours are visible in the online version of the article; http://dx.doi.org/10.3233/DMA-120947)
2.4. Immunohistochemical staining
3 µm sections were prepared for each case and after-
wards stained with Hematoxylin Eosin (H&E), intend-
ed for histological examination. When the patient’s
condition requires further investigation, estrogen and
progesterone receptors status (ER and PR) were deter-
mined.
Brieﬂy, we deparafﬁnized sections in xylene and we
rehydrated them through graded alcohols, then we used
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Fig. 2. Western blots with the 35C1 antibody on cell line and puriﬁed recombinant human His-Aurora-A protein. (a) lane 1: Hek 293 cells; (b)
lane 2: Hela cells; (c) with increasing concentration of the recombinant protein His-Aurora-A: lane 3: 0,25 µg, lane 4: 0,5 µg, lane 5: 0,75 µg,
lane 6: 1 µg, lane M: Protein molecular weight markers.
Table 2
Details about slides (n = 107)
Type of the tissue Number of slides
DCIV + IS + Non malignant tissue 54
DCIV + Non malignant tissue 33
DCIV + IS 5
DCIV 11
IS + Non malignant tissue 4
a Novolink polymer detection system (RE7150-K, Le-
ica, TN) as recommended in the instruction manual.
The slides were incubated with the primary antibody
Aurora A at 1:50 overnight in a humidity tray; and a
slid of colorectal carcinomawas included in each batch
as a positive control for Aurora A (Fig. 1A). A neg-
ative control was performed by omitting the primary
antibody and did not produce any visible background
staining (Fig. 1B).
The evaluation used for intensity of staining and sub-
cellular localization was performed in a blinded man-
ner. Intensity was scored from 0: no staining, +1:
weak, +2: moderate to +3: strong (Fig. 1C, D, E, F).
We also considered: range of intensity with the per-
centage of cell stained when the tumor was heteroge-
neous. When less than 10% of cell showed staining, it
was scored as negative. Altogether, these data allowed
to establish a semi-qualitative score calculated as fol-
lowing: % of cell (score1)+% of cell (score2)+ % of
cell (score3) = ﬁnal score.
2.5. Statistical analysis
The analysis of the results involving the expression
of the AuroraA protein and the various histological and
clinical parameters were made by using the chi-square
and regression linear performed with the program Sta-
tistical Package for Social Sciences (SPSS 13.0) and
Epi info 6. We considered that results were statisti-
cally signiﬁcant when p values were < 0.05, asterisks
indicate p < 0.05 (∗) and p < 0.01 (∗∗).
3. Results
Since antibody speciﬁcity is of great importance in
immunohistochemistry, we analyzed the speciﬁcity of
the Aurora A antibody prepared by the laboratory. The
speciﬁcity of theAuroraA antibodywas tested bywest-
ern blot performed with recombinant Aurora A protein
and cellular extracts. A single speciﬁc bandwas detect-
ed at 46 Kda and 50 Kda corresponding respectively to
cellular and to recombinant protein (Fig. 2).
The invasive Ductal Carcinoma (DCIV) and the ‘In
Situ’ (IS) tumors cells were analyzed alongwith the ad-
jacent normal mammary tissue in 54 slides, but in most
of the cases only two types of tissues were available.
Details concerning slides are in Table 2.
Using the autologous antibody, Aurora A protein ex-
pression was tested by IHC on breast tissue. Over-
expression was observed in 92.2% for Invasive Ductal
Carcinoma (DCIV) and in 91.9% for ‘In Situ’ Ductal
Carcinoma (IS). In the case of DCIV, Aurora A over-
expression was observed in 83.2% of the cases in both
nucleus and cytoplasm, while 4.2% in only nucleus and
12.6% in only cytoplasm. Whereas in IS the percent-
ages are respectively: 79.3%, 3.5% and 17.2%. The re-
sults present no signiﬁcant differences between Aurora
A expression and localization in DCIV and IS.
I. Ferchichi et al. / Assessment of Aurora A kinase expression in breast cancer: A tool for early diagnosis? 67
Table 3
Comparison of Aurora A expression and localization in malignant
and non malignant tissues
Aurora A Malignant Non malignant
Overexpression 99 [92.5%] 77 [84.6%] £
Negative expression 8 [7.5%] 14 [15.4%] £
Nuclear & Cytoplasmic 82 [82.8 %] 37 [48%] υ
Nuclear Or Cytoplasmic 17 [17.2%] 40 [52 %] υ
Only Nuclear 4 8
Only cytoplasmic 13 32
£: p = 0.07. υ: p = 0.000001∗∗ , OR = 5.21, RR = 2.31.
Table 4
Association between Aurora A expression in malignant tissue and
pathologic parameters
Pathologic parameters Aurora A expression
p
Age 0.30
SBR 0.06
Tumor size 0.20
RE 0.26
RP 0.01∗
Nodal status 0.02∗
Nuclear grade 0.02∗
Mitotic index 0.37
Altogether, the tumoral tissue has protein overex-
pression in 92.5% (Table 3). When it was possible, the
normal adjacent mammary tissues were included in the
study and we observed a weak and a moderate but not
a strong Aurora A expression in non malignant breast
tissue with a rate of 84.6% (Fig. 1G). No signiﬁcant
differences between Aurora A expression in malignant
and non malignant tissue is observed p = 0.07, even
if this protein seems less frequently expressed in non
malignant tissue (Table 3).
The subcellular localization of the protein in malig-
nant tissue was both cytoplasmic and nuclear (Fig. 1F)
in 82.8 % of the cases. In 4.1% of the cases the ex-
pression observed was only nuclear and in 13.1% was
only cytoplasmic (Fig. 1D). In normal tissues the dis-
tribution of the protein was as follows: 48% nuclear
and cytoplasmic, 41.6% cytoplasmic only and 10.4%
nuclear only.
The Aurora A localization proﬁle in both nucleus
and cytoplasm is correlatedwithmalignant tissue rather
than with non malignant tissue p = 0.000001∗∗, OR =
5.21, RR = 2.31; (Table 3).
The statistical study showed a correlation between
a high Aurora A expression with an elevated nuclear
grade (p = 0.021∗), as well as a low progesterone
receptor positivity (p = 0.016∗). Finally we found
an association between high Aurora A expression in
malignant tissue and positive nodal status (p = 0.021∗)
(Table 4).
4. Discussion
In this study, evidence has been provided for an over-
expression of Aurora A in tumoral breast cancer tis-
sue: DCIV and IS, in agreement with the previous
studies [41,43–45]. The overexpression of this protein
may be due to gene ampliﬁcation which was reported
in several studies [23,24], but the increase in the rate of
the protein may also be explained by the aberration of
the degradation systems of this&2 kinase [12–15].
Only the work of Nadler et al. [41] mentioned the
presence of the protein in the nucleus in breast cancer,
the other authors found only a cytoplasmic localization.
We found that this protein is often expressed in nucleus
and cytoplasm at the same time. In our study, we
obtained a relationship between a high expression of
Aurora A kinase and an elevated nuclear grade on in
agreement with the works of Royce et al. [45] and
Nadler et al. [41], on the one hand,andwith nodal status
positivity as well as with low progesterone receptor
expression in conformitywith theworks ofNadler et al.,
on the another hand. The relationship between Aurora
A expression and nuclear grade is expected according
to Aurora A function.
The overexpression of the Aurora A kinase by the
non-malignant tissue was reported by Hoque et al. [44],
but not by Tanaka et al. [43]. In this study, we ﬁnd that
non tumoral tissue overexpresses this protein at a fre-
quency of 84.6%. Thus observation goes to the logic of
the malignant processing; the tissue being morpholog-
ically healthy could have already begun its canceriza-
tion process. Indeed, we observed correlation between
tumoral and normal tissues from the same patient for
the Aurora A expression. However, there are differ-
ences in protein localization observed between tumor
and normal tissues, since the dual expression in nucle-
us and cytoplasm is associated with tumor. Less than
50% of normal tissue display such proﬁle expression
p = 0.000001∗∗, OR = 5.21, RR = 2.31. It is possible
that the presence of the protein in both nuclear and cy-
toplasmic compartments corresponds to an early or es-
tablished tumoral status. The shift of the protein from
the cytoplasmic expression to simultaneously expres-
sion in both nucleus and cytoplasm can be explained
by several mechanisms: taking into = consideration
that the STK15 gene ampliﬁcation is reported in breast
cancer in several studies [23,24], we can suggest that
the alternative splicing is altered and could change the
balance of the protein into nuclear isoforms during the
transformation [31,47]. However it remains unclear
how the splicing occurs in the context of gene ampliﬁ-
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cation. From another point of view, during canceriza-
tion process, the cell begins its transformation by ex-
pressing cytoplasmic isoforms before acquiring a more
aggressive aspect triggering the synthesis of the nucle-
ar isoforms. We can also assume that the protein is
expressed with all its isoforms as soon as the process
of malignancy is initiated but remains healthy in ap-
pearance; however, when the protein is exported to the
nucleus, the cell acquires a malignant phenotype. We
can eventually propose that early in the malignant pro-
cess, cell keeps an aberrant degradation system, which
recognizes and destroys the nuclear isoforms; as the
cancer process advances progressively; the degradation
machinery of the protein no longer recognizes all of
its isoforms [12–15] that is why the nuclear isoforms
appear. Otherwise, we can also suppose that in cancer
tissue, aurora A is differentially modiﬁed or regulated,
leading to its mislocalization in the nucleus. We think
that this result asks for more investigation, in order to
better understand the shift in the subcellular localiza-
tion during malignant transformation.
To recapitulate, we propose the following scenario:
a ﬁrst deregulation step in apparent healthy mammary
tissue leads to a high level translation of Aurora A in
the cytoplasm, in a second step, it is exported to nucle-
us; this process could be followed by a shift to tumor
status which would be characterized by the presence of
Aurora A protein in both nucleus and cytoplasm.
In fact, the overexpression and the localization of
this protein should be evaluated in order to be used as
a tool of early screening even before the cell and tis-
sue change their morphology and earlier than the ﬁrst
stage of cancer is evident in histology. The screening of
this pathology uses mammographywith Magnetic Res-
onance Imaging (MRI) [48] or Ultrasound (US) when
the patient has a dense breast tissue [49,50]. In addi-
tion, we need to analyze a “real” normal mammary tis-
sue from healthy women and make a long-term survey
to inspect the upcoming of every found proﬁle. Since
Aurora A is present in a normal cell only during the
G2 and Mitosis phases, and does not exist in quiescent
cells [51,52], it would be interesting to understand its
mechanisms of deregulation during carcinogenesis.
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